Zoryve Foam was Arcutis Biotherapeutics’s largest product and service line in fiscal 2025, bringing in $181.89M of $372.07M (49%).
| Product and Service | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|
| Zoryve Foam | — | $71.54M | $181.89M |
| Zoryve Cream 0.3% | $3.69M | $85.08M | $121.00M |
| Zoryve Cream 0.15% | — | $9.92M | $68.27M |
| Zoryve Cream 0.05% | — | — | $911.00K |
| Total | $3.69M | $166.54M | $372.07M |
Arcutis Biotherapeutics brought in $372.07M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Arcutis Biotherapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $166.54M. Zoryve Foam was the largest at $181.89M (48.9%), ahead of Zoryve Cream 0.3% at $121.00M (32.5%) and Zoryve Cream 0.15% at $68.27M (18.3%). The remaining line, Zoryve Cream 0.05%, brought in $911.00K.
Compared with fiscal 2024, Zoryve Cream 0.15% grew fastest, up 588.2% to $68.27M. Every line above 2% of revenue grew.
Arcutis Biotherapeutics began breaking out Zoryve Foam in fiscal 2024, Zoryve Cream 0.15% in fiscal 2024 and Zoryve Cream 0.05% in fiscal 2025.
Arcutis Biotherapeutics (ARQT) reports its revenue by product and service. In fiscal 2025, Zoryve Foam was its largest product and service line, bringing in $181.89M (48.9% of the total), followed by Zoryve Cream 0.3% at $121.00M (32.5%).
Zoryve Foam was Arcutis Biotherapeutics' largest product and service line in fiscal 2025, bringing in $181.89M, or 48.9% of the $372.07M total across its four product and service lines.
Every figure comes from Arcutis Biotherapeutics' annual financial filings, as reported. Each line keeps the name Arcutis Biotherapeutics gives it, and years follow its fiscal calendar.
Arcutis Biotherapeutics' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.